Feverfew: How Parthenolide Works

Feverfew's supposed active compound is parthenolide, a sesquiterpene lactone that makes up a fraction of a percent of the dried leaf. Almost everything you will read about how feverfew works is really about parthenolide, and almost every product that claims to be standardised is standardised to it.

The pharmacology is real. Parthenolide is not a vague “plant compound with antioxidant properties” — it has a specific chemical reactivity, a known molecular target in inflammation, and a documented action on the exact nerve population that generates migraine pain. It is one of the better-characterised natural products in the literature.

There is also a problem sitting underneath all of it, and this page does not bury it: when researchers gave people oral parthenolide and measured their blood, they could not detect any. That single finding constrains how much of the mechanism story can plausibly explain what happens when someone swallows a feverfew capsule. We will get there.

Table of Contents

1. The Molecule and Why Its Shape Matters
2. Serotonin and Platelets: The Original Mechanism
3. NF-κB: The Inflammation Master Switch
4. TRPA1 and the Trigeminal Nerve
5. Prostaglandins and Other Inflammatory Enzymes
6. The Bioavailability Problem
7. Is Parthenolide Even the Active Compound?
8. How Well Does Any of This Fit Migraine?
9. Parthenolide Outside Feverfew
10. What Would Actually Settle This
11. What the Mechanism Implies for Safety
12. Key Research Papers
13. Connections

The Molecule and Why Its Shape Matters

Parthenolide is a germacranolide sesquiterpene lactone: fifteen carbons arranged in a ten-membered ring, fused to a five-membered lactone ring, with an epoxide bridge on the large ring. Formula C₁₅H₂₀O₃, molecular weight about 248. It is concentrated in the leaves, flowering tops and seeds, and scarce in stalks and roots (Heptinstall 1992).

One structural feature explains most of its biology: the α-methylene-γ-lactone. That is a carbon-carbon double bond sitting next to the lactone's carbonyl group, and it makes the molecule an electrophile — chemically hungry for electrons. In practical terms it acts as a Michael acceptor: it reacts with sulphur-containing thiol (–SH) groups, particularly the cysteine residues in proteins, and forms a covalent bond.

Once you know that, several apparently unrelated observations line up:

• It inhibits proteins with a critical cysteine. Parthenolide does not have to fit a receptor pocket; it chemically modifies its target. That is why its targets are diverse.
• It is a contact allergen. Covalently modifying skin proteins creates new antigens, which is the textbook route to sesquiterpene lactone contact dermatitis. Parthenolide is a recognised Compositae sensitiser (Paulsen 2010) — the same chemistry that gives feverfew its pharmacology gives it its allergy problem.
• It is unstable. A reactive molecule degrades. Parthenolide levels fall during storage of powdered leaf (Heptinstall 1992), and in one dermatology study a feverfew-containing cream re-analysed two years later had no detectable parthenolide left (Paulsen 2010).

Chemical reactivity is simultaneously the reason parthenolide does anything, the reason it can sensitise skin, and the reason it will not sit in a bottle indefinitely. Those three facts are one fact.

Serotonin and Platelets: The Original Mechanism

The first mechanistic work came from the same Nottingham group running the clinical trials. In 1985 they showed that feverfew extracts inhibit secretory activity in blood platelets and in polymorphonuclear leucocytes (a type of white blood cell) — published in The Lancet alongside the emerging clinical interest (Heptinstall 1985).

The details are more specific than the summary suggests:

• Release of serotonin (5-HT) from platelets was inhibited when triggered by ADP, adrenaline, sodium arachidonate, collagen and the thromboxane analogue U46619 — a broad range of triggers.
• Platelet aggregation was consistently inhibited, but thromboxane synthesis was not. That distinguishes feverfew from aspirin, which works by blocking thromboxane production.
• Release of vitamin B₁₂-binding protein from white cells was also inhibited.
• Crucially, feverfew did not inhibit secretion triggered by the calcium ionophore A23187 — meaning it acts upstream of the final calcium-driven step, not on the machinery of secretion itself.

Follow-up work identified the likely mechanism as neutralisation of sulphydryl groups on platelet proteins (Heptinstall 1987; Heptinstall 1988) — exactly the Michael-acceptor chemistry described above, arrived at independently from the pharmacology side. A later comparison confirmed that parthenolide alone reproduces the antisecretory effect of whole feverfew extract on human platelets (Groenewegen 1990).

Why this was thought to matter for migraine: serotonin is central to migraine biology, platelets are a major reservoir of circulating serotonin, and one long-standing theory held that platelet serotonin release helps initiate attacks. Damping that release is a coherent idea.

It also has a practical consequence that has nothing to do with headaches. A small study in 1982 found altered platelet aggregation responses in people taking feverfew for migraine (Biggs 1982). Feverfew is mildly antiplatelet, which is why the safety advice about anticoagulants and surgery is not theoretical hand-waving — it comes straight from this mechanism.

NF-κB: The Inflammation Master Switch

The best-characterised molecular action of parthenolide has nothing specifically to do with migraine — it is general anti-inflammatory pharmacology.

NF-κB is a transcription factor that sits inactive in the cytoplasm, held there by an inhibitor protein called IκB. When a cell receives an inflammatory signal — TNF-α, bacterial products, oxidative stress — an enzyme complex called IκB kinase (IKK) tags IκB for destruction. NF-κB is released, moves into the nucleus, and switches on dozens of inflammatory genes: cytokines, adhesion molecules, COX-2, inducible nitric oxide synthase. It is the closest thing inflammation has to a master switch.

In 1999, a German group showed that parthenolide inhibits NF-κB by targeting the IκB kinase complex — blocking the switch rather than the downstream genes (Hehner 1999). Two years later, a chemical-biology group at Yale went further and showed parthenolide binds directly to IKK, with the effect traced to a specific cysteine residue in the kinase — the covalent chemistry made concrete (Kwok 2001).

This is genuinely good science and it is the reason parthenolide appears in thousands of papers across immunology and oncology. What it does not do by itself is explain migraine. NF-κB inhibition is a plausible contributor to the “neurogenic inflammation” component of a migraine attack — the sterile inflammatory response around meningeal vessels — but no trial has connected the two in humans, and the concentrations used in these cell studies are far above anything a capsule produces (see bioavailability).

TRPA1 and the Trigeminal Nerve

The most migraine-specific mechanism is also the most recent, and it is worth understanding because it explains something the older theories do not.

Migraine pain is generated by the trigeminovascular system: branches of the trigeminal nerve that supply the meninges and their blood vessels. When these fibres fire, they release CGRP (calcitonin gene-related peptide), which dilates meningeal vessels and sensitises pain pathways. CGRP is now such an established migraine mechanism that an entire modern drug class — the gepants and the anti-CGRP antibodies — targets it.

Those trigeminal fibres carry TRPA1, an ion channel that detects chemical irritants. TRPA1 is the sensor for the pungency of mustard oil, garlic, cinnamaldehyde and formalin, and it is activated by reactive electrophiles — it works by having reactive cysteines in its structure. Several known migraine triggers, including cigarette smoke and certain environmental chemicals, are TRPA1 agonists.

Parthenolide is an electrophile. So what happens when it meets TRPA1?

An Italian group at the University of Florence answered this in Pain in 2013 (Materazzi 2013). In transfected cells and in rat and mouse trigeminal neurons, parthenolide stimulates TRPA1 — but only as a partial agonist. After that initial stimulation it desensitises the channel and renders the peptidergic nerve terminals unresponsive to any subsequent stimulus. The consequences in rodents: nociceptive responses to trigeminal stimulation were abolished, CGRP release from trigeminal neurons was inhibited, and CGRP-mediated meningeal vasodilatation was blocked — whether it had been triggered by TRPA1 agonists or by unrelated stimuli.

The authors call this “nociceptor defunctionalisation.” It is the same pharmacological logic as capsaicin: a compound that first excites a nerve ending and then leaves it silent. It is an elegant explanation for how a daily preventive might blunt the trigger-to-attack pathway rather than block pain directly.

The honest caveats: this is rodent and cell work, not human. Concentrations in a dish are controlled in a way that oral dosing is not. And a partial agonist that first activates pain fibres raises an obvious question about the initial dose, which the study does not resolve in a human context.

Prostaglandins and Other Inflammatory Enzymes

Beyond NF-κB, feverfew extracts have been reported to inhibit a spread of inflammatory enzymes and mediators in laboratory systems: prostaglandin production, 5-lipoxygenase, phosphodiesterases 3 and 4, and the release of nitric oxide, PGE₂ and TNF-α from macrophages (Sur 2009). One systematic review flagged feverfew's COX-2 inhibiting effects as a theoretical concern for very long-term use in people with coronary disease — a reasonable caution given what is known about selective COX-2 inhibition, though there is no clinical evidence of harm from feverfew specifically (Saranitzky 2009).

A 2020 study of a feverfew water extract — which contains little parthenolide, since parthenolide is poorly water-soluble — still found anti-inflammatory and neuromodulatory activity in isolated tissue, including effects on serotonin turnover in rat cortex (Recinella 2020). Keep that result in mind for the next section.

The Bioavailability Problem

Here is the finding that every discussion of feverfew's mechanism ought to include and almost none do.

In 2004, oncology researchers at Indiana ran a phase I dose-escalation trial of feverfew in cancer patients, specifically to characterise parthenolide's pharmacokinetics — something that had never been done despite decades of use. Patients took a commercial feverfew tablet daily on a 28-day cycle, escalating from 1 mg to 2, 3 and 4 mg of parthenolide per day. Plasma parthenolide was measured by solid-phase extraction and mass spectrometry, with a detection limit of 0.5 ng/mL.

The result: at doses up to 4 mg daily there was no detectable parthenolide in plasma at all. The pharmacokinetic analysis could not be completed because there was nothing to measure. The authors concluded that purified parthenolide at higher doses would be needed for any therapeutic use (Curry 2004).

The trial also found no significant toxicity and never reached a maximum tolerated dose — useful safety information in its own right.

What to make of this. It is one small trial with one assay in cancer patients, and undetectable is not the same as absent: 0.5 ng/mL is a real but not extraordinary detection limit, and a compound can act locally — in the gut wall, on platelets in the portal circulation, on nerve endings — without reaching a measurable systemic concentration. A covalent binder can also do its work and disappear from plasma quickly, since it becomes attached to protein.

But it does place a hard constraint on the story. Cell studies of NF-κB inhibition typically use micromolar parthenolide. The gap between micromolar in a dish and undetectable in blood is several orders of magnitude. Any explanation of how a feverfew capsule prevents migraine has to work at concentrations far below the ones used to discover the mechanism. That does not make the mechanism wrong. It does mean the confident chain of reasoning — parthenolide blocks NF-κB, NF-κB drives neurogenic inflammation, therefore feverfew prevents migraine — has a missing link in the middle, and honest writing should say so.

Is Parthenolide Even the Active Compound?

The evidence points both ways, which is itself worth knowing if you are choosing a product standardised to parthenolide content.

For parthenolide being the active principle:

• The 1992 analytical study found that three physicochemical assays and a platelet bioassay gave consistent results, and concluded that “parthenolide appears to be mainly responsible for the antisecretory effects of extracts of feverfew” (Heptinstall 1992).
• Purified parthenolide reproduces whole-extract effects on platelets (Groenewegen 1990).
• It has a defined molecular target in IKK (Hehner 1999; Kwok 2001) and a defined action on trigeminal TRPA1 (Materazzi 2013).

Against parthenolide being the whole story:

• A parthenolide-depleted feverfew extract, developed by a consumer-health company specifically to remove the skin sensitiser, retained substantial anti-inflammatory activity: it inhibited 5-lipoxygenase, phosphodiesterase-3 and -4, and the release of nitric oxide, PGE₂, TNF-α, IL-2, IFN-γ and IL-4, and reduced dermatitis in animal models. Notably it did not inhibit TNF-induced NF-κB activity — confirming the depletion had worked — yet was still active by other routes, and in one model was more potent than whole feverfew (Sur 2009).
• A water extract, low in parthenolide by definition, still showed anti-inflammatory and serotonergic effects in isolated tissue (Recinella 2020).
• Feverfew contains dozens of other sesquiterpene lactones plus flavonoids and essential-oil components, few of which have been tested individually.
• Oral parthenolide is undetectable in plasma (Curry 2004), which sits awkwardly with it being the sole mediator of a systemic effect.

The practical reading: parthenolide is the best available quality marker — it tells you the material is real feverfew, harvested from the right plant parts, not degraded by age or heat, and processed in a way that preserves chemistry. That is genuinely worth paying for. It is a weaker claim to say a stated parthenolide percentage guarantees clinical effect. Buy standardisation as a proxy for manufacturing care, not as a guarantee of efficacy.

How Well Does Any of This Fit Migraine?

Scoring each mechanism against what we know about migraine:

The TRPA1 work is the most satisfying because it explains the clinical shape of feverfew's use. A defunctionalising agent would need repeated daily dosing to keep nerve terminals quiet, would prevent attacks rather than abort them, would take weeks to show its full effect, and might produce a rebound when withdrawn as nerve terminals recover their sensitivity. That is precisely how feverfew behaves clinically, including the withdrawal reaction. It is a hypothesis rather than a proof, but it is an unusually good one.

Parthenolide Outside Feverfew

Parthenolide has a substantial research life that has nothing to do with headaches, and it needs a clear boundary drawn around it, because the abstracts are exciting and the clinical reality is not.

Because NF-κB keeps cancer cells alive under stress, parthenolide attracted attention as an anti-cancer agent, particularly against leukaemia stem cells, which appear unusually dependent on NF-κB. Laboratory results have been striking, and a large literature has followed.

The clinical reality is the phase I trial described above: feverfew tablets delivering up to 4 mg of parthenolide daily produced no detectable plasma level, so the pharmacokinetic study could not even be completed (Curry 2004). Work since has focused on synthetic, water-soluble analogues such as dimethylamino-parthenolide, which is a different molecule, not something you can buy.

Feverfew is not a cancer treatment, and no responsible reading of this literature suggests otherwise. Anyone considering it during cancer treatment should also know that feverfew's antiplatelet activity is a real concern around thrombocytopenia and surgery, and that herb-drug interactions during chemotherapy need a pharmacist's input.

What Would Actually Settle This

Three studies, none of them done:

1. A proper pharmacokinetic study with a modern assay at doses people actually take, ideally measuring parthenolide-protein adducts rather than free parthenolide — a covalent binder may simply be invisible to a free-drug assay.
2. A head-to-head trial of standardised versus non-standardised feverfew in the same population. If product variability is the explanation for the mixed trial results, this settles it directly. If both arms perform identically, the standardisation story collapses.
3. A CGRP-linked human study — measuring whether feverfew or parthenolide affects CGRP release or trigeminal sensitisation in people, which would test the TRPA1 hypothesis where it counts.

Until then, feverfew's mechanism is a well-supported hypothesis with a documented gap between the concentrations that produce the effects in the laboratory and the concentrations a capsule delivers.

What the Mechanism Implies for Safety

The pharmacology predicts the safety profile rather neatly, which is a point in its favour:

• Antiplatelet effect → bleeding caution. Documented in human platelets and in feverfew users. Caution with warfarin, aspirin, clopidogrel and DOACs; stop about two weeks before surgery.
• Covalent protein binding → contact allergy. Parthenolide is a recognised Compositae sensitiser; cross-reactivity with ragweed, chrysanthemum, marigold and chamomile is expected, not surprising.
• Chemical reactivity → mucosal irritation. The mouth ulcers associated with chewing fresh leaves are the local version of the same chemistry.
• Nerve defunctionalisation → rebound on withdrawal. A plausible mechanistic account of post-feverfew syndrome, covered in Side Effects and Post-Feverfew Syndrome.
• Reactive electrophile → avoid in pregnancy. The only experimental reproductive screen, in rats, produced smaller fetuses and embryotoxicity in culture and concluded a full study was warranted (Yao 2006).

Key Research Papers

Every identifier was verified live against NCBI E-utilities before being written here.

Platelets, serotonin and the sulphydryl mechanism

1. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. The Lancet. 1985;1(8437):1071–1074.
2. Heptinstall S, Groenewegen WA, Spangenberg P, Lösche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. Journal of Pharmacy and Pharmacology. 1987;39(6):459–465.
3. Heptinstall S, Groenewegen WA, Spangenberg P, Lösche W. Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphydryl groups. Folia Haematologica. 1988;115(4):447–449.
4. Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. Journal of Pharmacy and Pharmacology. 1990;42(8):553–557.
5. Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. The Lancet. 1982;2(8301):776.

NF-κB and inflammatory signalling

1. Hehner SP, Hofmann TG, Dröge W, Schmitz ML. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. The Journal of Immunology. 1999;163(10):5617–5623.
2. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IκB kinase. Chemistry & Biology. 2001;8(8):759–766.
3. Sur R, Martin K, Liebel F, Lyte P, Shapiro S, Southall M. Anti-inflammatory activity of parthenolide-depleted feverfew (Tanacetum parthenium). Inflammopharmacology. 2009;17(1):42–49. The study showing activity survives removal of parthenolide.
4. Recinella L, Chiavaroli A, di Giacomo V, et al. Anti-inflammatory and neuromodulatory effects induced by Tanacetum parthenium water extract. Molecules. 2020;26(1).

Trigeminal nerves, TRPA1 and CGRP

1. Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain. 2013;154(12):2750–2758. The central modern mechanism paper — rodent and cell work.

Pharmacokinetics, chemistry and quality

1. Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs. 2004;22(3):299–305. No detectable plasma parthenolide at up to 4 mg/day.
2. Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew: estimation of commercial and authenticated feverfew products. Journal of Pharmacy and Pharmacology. 1992;44(5):391–395.
3. Jin P, Madieh S, Augsburger LL. Selected physical and chemical properties of feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance. AAPS PharmSciTech. 2008;9(1):22–30.
4. Brown AM, Edwards CM, Davey MR, Power JB, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in-vitro. Journal of Pharmacy and Pharmacology. 1997;49(5):558–561.

Allergy, reproduction and reviews

1. Paulsen E, Christensen LP, Fretté XC, Andersen KE. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients. Contact Dermatitis. 2010;63(3):146–150. Also documents parthenolide degradation over two years.
2. Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reproductive Toxicology. 2006;22(4):688–693.
3. Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements. 2009;6(2):91–103. Raises the COX-2 inhibition concern for long-term use.
4. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacognosy Reviews. 2011;5(9):103–110.

Live PubMed Searches

1. Parthenolide mechanism of action
2. Parthenolide, NF-κB and IKK
3. TRPA1, CGRP and trigeminal migraine
4. Sesquiterpene lactones as Michael acceptors
5. Parthenolide pharmacokinetics
6. DMAPT, the soluble parthenolide analogue
7. Feverfew and platelet serotonin release
8. Neurogenic inflammation in migraine

Connections

• All Herbs
• Feverfew Benefits — hub
• Migraine Prevention — what the trials found
• Choosing a Product and Dosing
• Side Effects and Post-Feverfew Syndrome
• Feverfew — the main herb page
• Migraine
• Neurology
• Butterbur — isopetasin acts on the same TRPA1 pathway
• Chamomile — another Asteraceae herb with sesquiterpene chemistry

Back to Table of Contents

×